Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2018-11-01 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Investor Presentation
Regulatory Filings
2018-11-01 English
Press Release
Regulatory Filings
2018-11-01 English
Financial Result Updates
Regulatory Filings
2018-11-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document text contains only references to omitted pictures and no substantive text content. The true document length is only 284 characters, which is very short and does not contain any financial data, report content, or announcements. Given the lack of any textual information or report content, this document cannot be classified as a full report or detailed filing. It is likely a placeholder or a minimal announcement without substantive data. According to the rules, such short documents with no report content fall under Regulatory Filings (RNS) as a fallback category.
2018-10-29 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the transfer of ownership of a pharmaceutical product's ANDA (Abbreviated New Drug Application) from Laurus Labs to CASI Pharmaceuticals. It discusses the transaction details, strategic focus, and company background. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about a business transaction, specifically a transfer of an asset related to pharmaceutical products. This fits best under Capital/Financing Update (CAP) as it relates to a transaction involving company assets and potential milestone payments. The document is not a full financial report, audit, or earnings release, nor is it a regulatory filing or legal proceeding. Therefore, the classification is CAP with high confidence.
2018-10-23 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (59 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of information, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2018-10-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.